Validation of the 2018 Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) Guidelines for Preventing Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
Masashi Amano(National Cerebral and Cardiovascular Center), Akihiro Hayashida(Sakakibara Hospital), Kaoru Dohi(Mie University), Kenji Ando(Kokura Memorial Hospital), Satoshi Yuda(Teine Keijinkai Hospital), Hiroaki Kitaoka(University of Kochi), Haruhiko Abe(Osaka National Hospital), Yasushi Sakata(The University of Osaka), Kunihiro Nishimura(National Cerebral and Cardiovascular Center), Toru Kubo(Kōchi University), Yusuke Yoshikawa(Kyoto University), Takeshi Kitai(National Cerebral and Cardiovascular Center), Moriaki Inoko(Hyogo Medical University), Shouji Matsushima(Hokkaido University), Yukichi Tokita(Nippon Medical School Hospital), Kazushige Kadota(Kurashiki Central Hospital), Takashi Omura(Sunagawa City Medical Center), Atsushi Okada(National Cerebral and Cardiovascular Center), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Tetsuya Kitamura, Yutaka Furukawa(Kobe City Medical Center General Hospital), Kenji Nakamura(Ise Red Cross Hospital), Toshihiro Tamura(Tenri Hospital), K Iwakura(Sakurabashi Watanabe Hospital), Takashi Tanigawa, Chisato Izumi(National Cerebral and Cardiovascular Center), Jun Masuda(The Cancer Institute Hospital), Takao Kato(Kyoto University)
Cited by 1
Related Papers
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|588
Vegetarian Diets and Blood Pressure
|JAMA Internal Medicine|2014|524